CENTENNIAL, Colo.--Nationally, prostate cancer is the second most common major cancer among men, and according to the North Dakota Statewide Cancer Registry, it was the most commonly occurring ...

The company behind an imaging agent meant to identify prostate cancer said it received FDA approval on Thursday for use in patients with suspected metastasis or recurrence.

Men with prostate cancers under the NHS would soon get non-invasive MRI scans for detections after a health body (National Institute for Health and Care Excellence or NICE) has given its approval ...

A new web-based tool utilizing AI can help pathologists detect prostate cancer faster, say Northeastern University researchers who developed the technology.

Arkansas Urology, the state’s largest and most innovative urology practice, is using a new radioactive diagnostic agent, Illuccix, that offers more precise detection of prostate cancer treatment ...

Clinicians and patients unsure whether to opt for conservative active surveillance or radical treatment for nonmetastatic prostate cancer can use a new, novel, free online tool.

Joseph Camunas lost his father to prostate cancer. And his younger brother was diagnosed with the disease at age 50. So when doctors found a slight elevation in his annual PSA blood test, Camunas ...

Researchers have found that it may not be necessary to look for tumors directly in patients with prostate cancer — analyzing non-tumor tissue may be an effective option, according to study ...

A comprehensive, clinical nomogram tool, the Sunnybrook Prostate Cancer Risk Calculator -- the first to use all known risk factors for prostate cancer -- is available online to help men determine ...

A new computational algorithm to help predict a man's individual's risk of developing prostate cancer has been developed by researchers at the University of Cambridge.

In this Review, the authors describe artificial neural networks (ANNs), which are mathematical tools used in medicine for cancer diagnosis, staging and recurrence prediction. With an emphasis on ...

SAN DIEGO -- An algorithm-based decision tool eliminated inappropriate prescribing of bone-modifying agents (BMA) in patients with advanced prostate cancer, according to a VA-based study. Prior to ...